482 related articles for article (PubMed ID: 15119543)
1. Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes.
Solans-Laqué R; Pérez-Bocanegra C; Salud-Salvia A; Fonollosa-Plá V; Rodrigo MJ; Armadans L; Simeón-Aznar CP; Vilardell-Tarres M
Lupus; 2004; 13(3):159-64. PubMed ID: 15119543
[TBL] [Abstract][Full Text] [Related]
2. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases.
Clegg DO; Williams HJ; Singer JZ; Steen VD; Schlegel S; Ziminski C; Alarcón GS; Luggen ME; Polisson RP; Willkens RF
J Rheumatol; 1991 Sep; 18(9):1340-3. PubMed ID: 1757935
[TBL] [Abstract][Full Text] [Related]
3. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile: data from a tertiary hospital in Shanghai, China.
Yang Z; Ren Y; Liu D; Lin F; Liang Y
APMIS; 2016 Sep; 124(9):805-11. PubMed ID: 27328803
[TBL] [Abstract][Full Text] [Related]
5. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases.
Salonen EM; Miettinen A; Walle TK; Koskenmies S; Kere J; Julkunen H
Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of antinuclear antibodies in connective tissue disease.
Pahor A; Krajnc I; Gorenjak M; Holc I
Wien Klin Wochenschr; 1998 May; 110(9):338-41. PubMed ID: 9629626
[TBL] [Abstract][Full Text] [Related]
7. Application of anti-DFS70 antibody and specific autoantibody test algorithms to patients with the dense fine speckled pattern on HEp-2 cells.
Lee H; Kim Y; Han K; Oh EJ
Scand J Rheumatol; 2016; 45(2):122-8. PubMed ID: 26643611
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic significance of different antinuclear antibodies in more than 1000 consecutive Albanian patients with rheumatic diseases.
Sulcebe G; Morcka K
Clin Exp Rheumatol; 1992; 10(3):255-61. PubMed ID: 1582070
[TBL] [Abstract][Full Text] [Related]
9. [Prevalence and diagnostic value of antinuclear antibodies without identified antigenic target: a retrospective study of 90 patients].
Feki S; Frikha F; Ben Hadj Hmida Y; Abed S; Ben Ayed M; Turki H; Hachicha J; Baklouti S; Bahloul Z; Masmoudi H
Rev Med Interne; 2012 Sep; 33(9):475-81. PubMed ID: 22658165
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of autoantibodies (ANA, anti ds-DNA, ENA, IMF) and rheumatic syndromes in patients with lymphoproliferative diseases.
Chloraki-Bobota A; Megalakaki C; Repousis P; Chalkiopoulou I; Lalaki I; Trafalis DT; Athanassiou AE; Mitsouli-Mentzikof C
J BUON; 2006; 11(4):485-9. PubMed ID: 17309182
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of systemic sclerosis, scleroderma-like syndromes and neoplastic diseases.
Ciołkiewicz M; Domysławska I; Ciołkiewicz A; Klimiuk PA; Kuryliszyn-Moskal A
Pol Arch Med Wewn; 2008 Mar; 118(3):119-26. PubMed ID: 18476458
[TBL] [Abstract][Full Text] [Related]
12. [Antinuclear antibodies in rheumatology].
Zuber M
Z Rheumatol; 1994; 53(6):327-34. PubMed ID: 7871904
[TBL] [Abstract][Full Text] [Related]
13. Performance of antinuclear antibody connective tissue disease screen.
López-Hoyos M; Rodríguez-Valverde V; Martinez-Taboada V
Ann N Y Acad Sci; 2007 Aug; 1109():322-9. PubMed ID: 17785321
[TBL] [Abstract][Full Text] [Related]
14. Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases.
Bossuyt X; De Langhe E; Borghi MO; Meroni PL
Nat Rev Rheumatol; 2020 Dec; 16(12):715-726. PubMed ID: 33154583
[TBL] [Abstract][Full Text] [Related]
15. [Newer approach of screening test for antinuclear antibodies: an enzyme-linked immunosorbent assay detecting antinuclear antibodies characteristic of connective tissue diseases].
Asanuma H; Miyake J; Miyawaki S
Nihon Rinsho Meneki Gakkai Kaishi; 1997 Oct; 20(5):417-27. PubMed ID: 9391305
[TBL] [Abstract][Full Text] [Related]
16. Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study.
Compagno M; Jacobsen S; Rekvig OP; Truedsson L; Heegaard NH; Nossent J; Jönsen A; Jacobsen RS; Eilertsen GØ; Sturfelt G; Bengtsson AA
Scand J Rheumatol; 2013; 42(4):311-6. PubMed ID: 23496224
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies Against DFS70/LEDGF Exclusion Markers for Systemic Autoimmune Rheumatic Diseases (SARD).
Seelig CA; Bauer O; Seelig HP
Clin Lab; 2016; 62(4):499-517. PubMed ID: 27215068
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of paraneoplastic rheumatic syndromes and their antibody profile among patients with solid tumours.
Rugienė R; Dadonienė J; Aleknavičius E; Tikuišis R; Distler J; Schett G; Venalis P; Venalis A
Clin Rheumatol; 2011 Mar; 30(3):373-80. PubMed ID: 21225302
[TBL] [Abstract][Full Text] [Related]
19. [Sharp's syndrome. Clinical, immunological and nosographic aspects].
Scagliusi P; Muratore M; Martiradonna A; Berlingerio G; Carrozzo M
Minerva Med; 1980 Dec; 71(50):3655-63. PubMed ID: 6161325
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of 10 patients with paraneoplastic rheumatologic musculoskeletal manifestations.
Yamashita H; Ueda Y; Ozaki T; Tsuchiya H; Takahashi Y; Kaneko H; Kano T; Mimori A
Mod Rheumatol; 2014 May; 24(3):492-8. PubMed ID: 24252036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
